CTCELLS Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 12

Employees

  • Latest Deal Type
  • Series B
  • (In Progress)

  • Latest Deal Amount
  • $6.66M

  • Investors
  • 9

CTCELLS General Information

Description

Operator of a cancer diagnostics and drug development platform intended to improve patient outcomes by matching cancer characteristics with the most suitable therapies. The company specializes in drug optimization and membrane-bound protein technology that attaches proteins to natural killer (NK) cell membranes and myelin basic protein (MBP) enhanced Natural Killer (NK) cells to demonstrate prolonged survival and heightened infiltration abilities, enabling patients to reduce the risk of side effects such as immune side effects and maintain the activity of NK cells.

Contact Information

Website
www.ctcells.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Number 208-B, R7, 333 Technojungang-daero
  • Hyeonpung-eup, Dalseong-gun
  • Daegu
  • South Korea
+82
Primary Industry
Diagnostic Equipment
Other Industries
Drug Delivery
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Number 208-B, R7, 333 Technojungang-daero
  • Hyeonpung-eup, Dalseong-gun
  • Daegu
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CTCELLS Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series B) 09-Apr-2026 $6.66M In Progress Generating Revenue
6. Accelerator/Incubator 28-Nov-2025 Completed Startup
5. Early Stage VC 22-Mar-2022 Completed Generating Revenue
4. Early Stage VC (Series A) 21-Apr-2021 Completed Generating Revenue
3. Accelerator/Incubator 01-Sep-2020 Completed Startup
2. Seed Round 31-Aug-2020 Completed Startup
1. Accelerator/Incubator Completed Startup
To view CTCELLS’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

CTCELLS Patents

  • 36

    Total Documents Applications and Grants

  • Total Patents Families

  • 12

    Granted

  • 12

    Pending

  • Expiring in next 12 mo

CTCELLS Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2026142474-A Material separation disc and material separation apparatus containing the same. Pending 26-Feb-2025
EP-4799728-A1 Material separation disc and material separation device comprising the same Pending 26-Feb-2025
US-20260249310-A1 Material separation disc and material separation device comprising the same Pending 26-Feb-2025
WO-2024106996-A1 Rare cell isolation device using centrifugal force Inactive 18-Nov-2022
WO-2024107010-A1 Method for differentiation from undifferentiated stem cells into natural killer cells and use thereof Inactive 17-Nov-2022 C12N5/0646
To view CTCELLS’s complete patent history, request access »

CTCELLS Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CTCELLS Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
InterVest Venture Capital Minority
Mirae Asset Capital Venture Capital Minority
Chungnam National University Technology Holdings Venture Capital Minority
Enlight Ventures Venture Capital Minority
KB Investment Venture Capital Minority
You’re viewing 5 of 9 investors. Get the full list »

CTCELLS Investments (1)

CTCELLS’s most recent deal was a Corporate Asset Purchase with Gom & Company (2039 Square Meters of Land and Building Property in Seoul, South Korea) for . The deal was made on 28-Jul-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Gom & Company (2039 Square Meters of Land and Building Property in Seoul, South Korea) 28-Jul-2022 Corporate Asset Purchase Buildings and Property
To view CTCELLS’s complete investments history, request access »

Ready to get started?

Request a free trial

CTCELLS FAQs

  • When was CTCELLS founded?

    CTCELLS was founded in 2018.

  • Where is CTCELLS headquartered?

    CTCELLS is headquartered in Daegu, South Korea.

  • What is the size of CTCELLS?

    CTCELLS has 12 total employees.

  • What industry is CTCELLS in?

    CTCELLS’s primary industry is Diagnostic Equipment.

  • Is CTCELLS a private or public company?

    CTCELLS is a Private company.

  • What is CTCELLS’s current revenue?

    The current revenue for CTCELLS is .

  • How much funding has CTCELLS raised over time?

    CTCELLS has raised $16.2M.

  • Who are CTCELLS’s investors?

    InterVest, Mirae Asset Capital, Chungnam National University Technology Holdings, Enlight Ventures, and KB Investment are 5 of 9 investors who have invested in CTCELLS.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process